

Our Ref: P11085 WO/MH/ASB.ek

Your Ref:

Date: 21 July 2004

**BY FACSIMILE AND COURIER**

European Patent Office  
Erhardtstrasse 27  
D-80331 Munich  
GERMANY

Dear Sir

**International Patent Application No. PCT/GB03/03040**  
**Reckitt Benckiser Healthcare (UK) Limited**

We are writing in response to the Written Opinion dated 15 April 2004 and issued in connection with the above-identified International patent application. In addition we are filing, herewith, in triplicate new pages 23-25 comprising a new set of claims 1-15 to replace claims 1-20 on file. New pages 23-25 replace pages 26-28 on file.

In addition, we are filing new pages of the description to conform with the new claims. We are filing, herewith, in triplicate new pages 1-7 to replace pages 1-7 on file. We also are cancelling pages 23, 24 and 25 presently on file.

We enclose a copy of each of the new pages and the cancelled pages showing the proposed changes in manuscript for the Examiner's assistance.

At Section 2 of the Written Opinion, the Examiner raises novelty objections in relation to certain of the claims in view of D1-D4. In view of these objections, the claims have been amended so that claim 1 is directed to an ingestible composition comprising ispaghula, colloidal silica and an ingestible surfactant. The composition is in a form so that when it is used, the composition is dispersed in the liquid prior to ingestion. The composition, therefore, is preferably in particulate or granular form prior to use. Basis for new claim 1 can be found in claims 1 and 7 presently on file and at page 7, first paragraph of the description.

We are of the view that the claims newly submitted are novel over all of the prior art cited by the Examiner.

D1 relates solely to bran containing products. In addition, the form of the composition is entirely different to the present invention. The products of this invention may be coated to form mucilage. The invention relates to properties of this coating. Therefore, this reference is not relevant to the present invention.

D2 relates to composition comprising gourd powder to provide a novel food source. Therefore, at no point is D2 relevant to compositions containing ispaghula. Furthermore, at no point is this reference relevant to the wetting properties of ispaghula. For these reasons, therefore, we do not believe that D2 is relevant to the present invention.

D3 provides a palatable pre-mixed bran drink. An essential feature of this drink is that it comprises heat treated, de-gelled bran. At no point is this reference relevant to the problems associated with compositions comprising ispaghula which have the benefit of being dispersible in a liquid prior to ingestion. The bran containing product of D3 is already provided as a suspension. Hence, the properties of a suspension do not relate to the properties of a composition which can be dispersed easily in a liquid prior to use, without the use of mechanical agitators and other industrial processes.

D4 relates to a dietary supplement which limits the assimilation of dietary fats during digestion. An essential feature of the dietary composition provided by this invention is that the dietary fibre is combined with a surfactant which comprises chickweed, together with an emulsifying agent comprising lecithin. Neither of these are essential features nor are they in any way relevant to our invention. The Examiner has relied on the disclosure in D4 which relates to a combination of these ingredients together with silica gel. This is exemplified in Example 2. However, the silica gel added to the compositions of D4 would fail to achieve the synergistic properties surprisingly found of the composition of the present invention. The silica gel used by D4 is an excipient agent which would be added to the supplements of D4 to keep the dietary supplement dry, a characteristic required in order for the composition to be pressed into tablets. This is described in detail in Example 2 of D4. In contrast, the colloidal silica of the composition of the present invention is used as a wetting agent and, therefore, has completely different properties to the silica gel disclosed in D4. Hence, the present invention is novel over D4.

At section 3 of the Written Opinion, the Examiner is of the view that novel features of the present invention would be the customary practice of the skilled person in this field and therefore, would lack an inventive step. However, we do not agree with the Examiner and would take this opportunity to point out the advantageous features of the present invention which would be wholly surprising to the skilled person from his own common general knowledge and indeed from the prior art references D1-D4.

The present invention relates to a composition which comprises ispaghula as a bulking agent. For ease of use, the composition should be provided to the user in a particulate or granular form so that, in use, it is added to liquid, becomes dispersed and is easily drunk by the user as a liquid. However, because of the properties of the ispaghula it is difficult to achieve satisfactory dispersion of the composition in a liquid by simply adding the ispaghula to a liquid and stirring. Therefore, although the properties of ispaghula as a bulking agent to alleviate the symptoms of constipation and other digestive dysfunctions are extremely beneficial, it is also essential that the dispersion of the composition into a liquid results in a form of dispersion which is easy to consume, for example, disperses quickly and does not form a gel-like liquid which would be difficult for the patient to swallow. Therefore, there is a need for an ingestible composition which disperses easily in an aqueous liquid and in addition can be manufactured with ease of handling. This is described in detail at page 2 of the present specification.


The present inventors have surprisingly found that if ispaghula is combined with ingestible colloidal silica and an ingestible surfactant, the colloidal silica and surfactant act together synergistically in order to improve significantly the rate at which the composition disperses in water or other ingestible liquids. There is no teaching in the prior art which would have led the skilled person to expect that a combination of these two ingredients, when added to ispaghula, would result in these significant benefits.

The data provided in the examples supports this conclusion. The data in the specification shows that when a composition comprises ispaghula and an ingestible surfactant only, or ispaghula and colloidal silica only, the wetting properties of the composition are far inferior compared to a composition which comprises ispaghula with a combination of the colloidal silica and the ingestible surfactant. The comparison results presented in the examples demonstrate that although using an ingestible surfactant with ispaghula or colloidal silica with ispaghula only improves the wettability of the ispaghula compared to the ispaghula alone, using a combination of these two ingredients with ispaghula significantly improves the wettability of the ispaghula, the increase far exceeds the skilled person's expectations. The effect of these two ingredients is synergistic and this would be wholly unexpected by the skilled person from his knowledge of the prior art.

For this reason, therefore, we submit that the claims newly presented to the Examiner are inventive over the prior art cited in the Written Opinion.

We look forward to receiving a positive International Preliminary Examination Report.

Yours faithfully  
RECKITT BENCKISER plc

A handwritten signature in black ink, appearing to be 'ASB', written over the printed name and company of the signatory.

Andrew S Brown  
European Patent Attorney

Encs.

Improvements In and Relating to Medicinal Compositions

The present invention relates to medicinal compositions comprising fibre bulking agents.

5

Ingestible fibre- compositions for the relief of gastric and digestive dysfunctions are known. Examples of such compositions include granular psyllium husk fibre (ispaghula) intended to be stirred in measured amounts  
10 into a volume of liquid, usually water or soft drinks. After stirring, the drinking composition is intended to be quickly imbibed due to the propensity of the ispaghula to absorb water readily and swell to form a viscous gel-like mass. It is the property of water absorption which has  
15 the desired characteristic of fibre or saccharide-containing ingestible compositions for gastric and digestive dysfunctions. Once the fibre or saccharide-containing composition has absorbed water to produce the gel-like mass, the mass is relatively insoluble and  
20 fibrous, and is transported through the gut quickly with minimal digestion, helping to alleviate constipation and other digestive dysfunctions.

Other forms, such as capsules forms for ingestion, are  
25 also available, such capsules being designed to be broken down in the gut, wherein the released fibre or saccharide bulking agent absorbs water from the gut to form the viscous mass.

30 However, for beneficial ease-of-use properties, a particulate form is particularly advantageous to the end user, as this can be stirred into a volume of liquid, for a more pleasant taste, and the granular form of the fibre

absorbs water from the gut more quickly than a capsule form. However, there are a number of problems involved in using a granular form of the fibre-containing ingestible compositions.

5

Primarily, it is desirable for the ingestible compositions to disperse easily in liquid, for the user's convenience and/or so that the resultant drink is more palatable and/or easier to swallow. Any new composition must be as  
10 good as or, preferably, better than, existing compositions in this respect.

Secondly, the handling of some ingestible fibre-containing compositions is not straightforward. For  
15 example in commercial production ispaghula is milled then isopropyl alcohol and a granulating agent polyvinyl pyrrolidone are added. These steps aid handling of the compositions during manufacturing, before the isopropyl alcohol is removed prior to packaging the product for  
20 sale. The granulation also aids the dispersion of the ispaghula into a volume of liquid, prior to ingestion. However, the use of the granulating agent and isopropyl alcohol increases the cost of production and the use of the isopropyl alcohol is undesirable from an environmental  
25 and a health and safety perspective.

Thus, from the foregoing, it is apparent that there is a need for the provision of an ingestible composition which comprises a fibre bulking agent, in which the ingestible  
30 composition disperses easily in an aqueous liquid and/or is of improved manufacture.

It has now been determined that an ingestible composition comprising a psyllium husk fibre bulking agent (ispaghula), colloidal silica in conjunction with an ingestible surfactant, can offer benefit in the manufacture of the ingestible composition, and can increase the rate at which the ingestible composition disperses in water or other ingestible liquid.

Therefore, according to the present invention there is provided an ingestible composition comprising ispaghula, colloidal silica and an ingestible surfactant wherein said composition is in a form so that in use it is dispersed in a liquid prior to ingestion.

The presence of both an ingestible silica and an ingestible surfactant can confer significant, eg synergistic, benefits. For example, the ternary composition of the ispaghula has outstanding wettability properties, and is easy to manufacture, for example by simple blending.

Suitably the fibre bulking agent is a natural ingestible fibre (by which term we include herein fibre extracts). Plant-derived fibre bulking agents from psyllium husk fibre (ispaghula) are used.

The ispaghula may comprise whole ispaghula seeds, but preferably at least part of the ispaghula comprises separated ispaghula seed husks. More preferably the ispaghula comprises at least 50% wt separated ispaghula husks, most preferably at least 95% wt separated ispaghula husks. Suitably the remainder of the ispaghula comprises other seed parts and/or other ispaghula plant materials. In preferred compositions the seed kernels themselves have been substantially removed to leave the husks.

10

15

20

25

30

Suitably the fibre bulking agent is present in the ingestible composition in an amount of at least 10wt%,  
5 preferably at least 30wt%, and most preferably at least 40wt% of the total weight of the ingestible composition.

Suitably the fibre bulking agent is present in the ingestible composition in an amount up to 90wt%,  
10 preferably up to 80wt%, and most preferably up to 75wt% of the total weight of the ingestible composition.

15

20

25

30

Suitably the colloidal silica is fumed or precipitated synthetic or natural silica. The silica may be amorphous or crystalline.

- 5 Suitably the mean particle size of the silica is at least 5nm, preferably at least 10nm.

Suitably the mean particle size of the silica is up to 5 $\mu$ m, preferably up to 0.75 $\mu$ m, more preferably up to 0.5 $\mu$ m,  
10 and most preferably up to 0.2 $\mu$ m.

One suitable silica material is Syloid 244 which is amorphous silica, has a mean particle size of about 3 $\mu$ m and is provided by W R Grace & Co. Another suitable  
15 silica materials is Silox 15, also from W R Grace & Co., and which has a mean particle size of about 4 $\mu$ m.

Another suitable silica material is Huber Zep 49 which is amorphous silica from J M Huber Corporation and contains  
20 about 1 wt% alumina.

Another suitable silica is Aerosil 200 from Degussa Company. It contains less than 0.05 wt% alumina and has a mean particle size of 12 nm.

25

30

The silica is colloidal silica (silicon dioxide), and a preferred silica is a colloidal silica which is sold under the trade mark CAB-O-SIL, by Cabot Inc, USA.

- 5 Suitably the specific surface area of the silica is at least  $50\text{m}^2 \text{g}^{-1}$ , preferably at least  $150\text{m}^2 \text{g}^{-1}$ .

- Suitably the specific surface area of the silica is up to  $400\text{m}^2 \text{g}^{-1}$ , preferably up to  $300\text{m}^2 \text{g}^{-1}$  most preferably up to  
10  $200\text{m}^2 \text{g}^{-1}$ .

- Suitably the silica is present in the ingestible composition in an amount at least 0.01wt%, preferably at least 0.05wt%, more preferably at least 0.1wt% and most  
15 preferably at least 0.25wt%, of the total weight of the ingestible composition.

- The upper limit of silica in the ingestible composition may be up to 11 wt%. Suitably the silica may be present  
20 in the ingestible composition in an amount up to 5wt%, preferably up to 2wt%, more preferably up to 1wt%, and most preferably up to 0.6wt%, of the total weight of the ingestible composition.

- 25 Preferably the ingestible surfactant is a polyethylene-, polypropylene-, or polyoxyethylene-based surfactant. Suitable polyethylene or polyoxyethylene-based surfactants include polyethylene glycols and polyoxyethylene sorbitan fatty acid esters (polysorbates).

30

Suitable polyethylene glycols have a molecular weight of between 200 and 40,000, preferably between 200 and 1,000, and more preferably between 200 and 600. Suitable

5 Claims

1. An ingestible composition comprising ispaghula, colloidal silica, and an ingestible surfactant wherein said composition is in a form so that in use it is  
10 dispersed in a liquid prior to ingestion.

2. An ingestible composition according to claim 1 wherein said composition in particulate or granular form.

15 3. An ingestible composition as claimed in any preceding claim wherein the particle size of the silica is between 5nm and 5 $\mu$ m.

4. An ingestible composition as claimed in any preceding  
20 claim wherein the specific surface area of the silica is between 50 and 400gm<sup>-2</sup>.

5. An ingestible composition as claimed in any preceding claim wherein the silica is present in an amount of  
25 between 0.01wt% and 5wt% of the total weight of the ingestible composition.

6. An ingestible composition as claimed in any preceding claim, wherein the ingestible surfactant is a  
30 polyethylene-, polypropylene-, or polyoxyethylene-based surfactant.

7. An ingestible composition as claimed in claim 11 wherein the polyethylene-based surfactant is a  
35 polyethylene glycol.

5 8. An ingestible composition as claimed in claim 12 wherein the polyethylene glycol has a molecular weight of between 200 and 40,000, preferably between 200 and 1,000.

9. An ingestible composition as claimed in claim 11  
10 wherein the polyoxyethylene-based surfactant is a polyoxyethylene sorbitan fatty acid ester.

10. An ingestible composition as claimed in claim 11, wherein the surfactant is a polyoxyethylene monostearate  
15 or a glycerol polyethylene glycol oxystearate.

11. An ingestible composition as claimed in any preceding claim wherein the ingestible surfactant is present in an amount of between 0.01wt% and 5wt% of the total weight of  
20 the ingestible composition.

12. An ingestible composition as claimed in claim 16 wherein the ingestible surfactant is polyethylene glycol and is present in an amount of between 0.1wt% and 2wt% of  
25 the total weight of the ingestible composition.

13. An ingestible composition as claimed in claim 16 wherein the surfactant is a polyoxyethylene sorbitan fatty acid ester and is present in an amount of between 1wt% and  
30 2wt% of the total weight of the ingestible composition.19.

14. A method of making an ingestible composition comprising ispaghula, colloidal silica, and an ingestible surfactant, the method comprising the step of blending the  
35 ispaghula with the colloidal silica and the ingestible surfactant; preferably without the employment of isopropyl alcohol or more preferably of any solvent; and preferably

5 without the employment of polyvinyl pyrrolidone or more  
preferably of any granulating agent.

15. An ingestible composition or its manufacture  
substantially as described herein.

10

15

Improvements In and Relating to Medicinal Compositions

The present invention relates to medicinal compositions comprising fibre ~~or saccharide~~ bulking agents.

Ingestible fibre- ~~or saccharide-containing~~ compositions for the relief of gastric and digestive dysfunctions are known. Examples of such compositions include granular psyllium husk fibre (ispaghula) intended to be stirred in measured amounts into a volume of liquid, usually water or soft drinks. After stirring, the drinking composition is intended to be quickly imbibed due to the propensity of the ispaghula to absorb water readily and swell to form a viscous gel-like mass. It is the property of water absorption which has the desired characteristic of fibre or saccharide-containing ingestible compositions for gastric and digestive dysfunctions. Once the fibre or saccharide-containing composition has absorbed water to produce the gel-like mass, the mass is relatively insoluble and fibrous, and is transported through the gut quickly with minimal digestion, helping to alleviate constipation and other digestive dysfunctions.

Other forms, such as capsules forms for ingestion, are also available, such capsules being designed to be broken down in the gut, wherein the released fibre or saccharide bulking agent absorbs water from the gut to form the viscous mass.

However, for beneficial ease-of-use properties, a particulate form is particularly advantageous to the end user, as this can be stirred into a volume of liquid, for a more pleasant taste, and the granular form of the fibre

p ~~or saccharide~~ absorbs water from the gut more quickly than a capsule form. However, there are a number of problems involved in using a granular form of the fibre- ~~or saccharide~~, containing ingestible compositions.

5

Primarily, it is desirable for the ingestible compositions to disperse easily in liquid, for the user's convenience and/or so that the resultant drink is more palatable and/or easier to swallow. Any new composition must be as  
10 good as or, preferably, better than, existing compositions in this respect.

Secondly, the handling of some ingestible fibre- ~~or saccharide~~-containing compositions is not straightforward.  
l  
15 For example in commercial production ispaghula is milled then isopropyl alcohol and a granulating agent polyvinyl pyrrolidone are added. These steps aid handling of the compositions during manufacturing, before the isopropyl alcohol is removed prior to packaging the product for  
20 sale. The granulation also aids the dispersion of the ispaghula into a volume of liquid, prior to ingestion. However, the use of the granulating agent and isopropyl alcohol increases the cost of production and the use of the isopropyl alcohol is undesirable from an environmental  
25 and a health and safety perspective.

Thus, from the foregoing, it is apparent that there is a need for the provision of an ingestible composition which comprises a fibre ~~or saccharide~~ bulking agent, in which  
p  
30 the ingestible composition disperses easily in an aqueous liquid and/or is of improved manufacture.

a psyllium husk fibre bulking agent (ispaghula)

It has now been determined that an ingestible composition comprising a fibre or saccharide bulking agent, which also includes an ingestible <sup>colloidal</sup> silica in conjunction with an ingestible surfactant, can offer benefit in the manufacture of the ingestible composition, and can increase the rate at which the ingestible composition disperses in water or other ingestible liquid.

Therefore, according to the present invention there is provided an ingestible composition comprising a <sup>ispaghula</sup> fibre or saccharide bulking agent, an <sup>colloidal</sup> ingestible silica and an ingestible surfactant wherein said composition is in a form so that in use it is dispersed in a liquid prior to ingestion.

According to a second aspect of the invention there is provided an ingestible composition comprising a fibre bulking agent selected from ispaghula or a bran, an ingestible silica, and an ingestible surfactant.

The presence of both an ingestible silica and an ingestible surfactant can confer significant, eg synergistic, benefits. For example, when the fibre or saccharide bulking agent ~~is~~ ispaghula the ternary composition has outstanding wettability properties, and is easy to manufacture, for example by simple blending.

of the ispaghula

Suitably the fibre or saccharide bulking agent is a natural ingestible fibre (by which term we include herein fibre extracts). Plant-derived fibre bulking agents are preferred, such as cellulose or derivatives thereof, from psyllium husk fibre (ispaghula), or brans such as corn, oat, wheat or rice brans. Animal-derived fibre, fruit-

Simply refer to psyllium husk fibre (ispaghula) and omit reference to other fibres.

Continued  
from  
previous  
page  
CTT/2/7/64

derived fibre and/or synthetic ingestible fibres may also be used. Examples include barley fibre, pea fibre, sugar beet fibre and  $\beta$ -glucan.

- 5 Particularly preferred as a fibre bulking agent is ispaghula.

- The ispaghula may comprise whole ispaghula seeds, but preferably at least part of the ispaghula comprises  
10 separated ispaghula seed husks. More preferably the ispaghula comprises at least 50% wt separated ispaghula husks, most preferably at least 95% wt separated ispaghula husks. Suitably the remainder of the ispaghula comprises other seed parts and/or other ispaghula plant materials.  
15 In preferred compositions the seed kernels themselves have been substantially removed to leave the husks.

- If the bulking agent is a saccharide-containing bulking agent it is suitably a polysaccharide, an arabinoxylan, a  
20 galactomannan, a glucomannan, preferably an algin, especially alginic acid or a salt derivative thereof, such as calcium alginate, magnesium alginate, sodium alginate or potassium alginate.

- omit this section CTT 2/7/64  
25 Algins may be found in and isolated from various organisms, in particular from algae belonging to the order *Phaeophyceae* and soil bacteria such as *Azotobacter vinelandii* and *Azotobacter crococcum* and from several strains of *Pseudomonas* bacteria. Common algal sources of  
30 algins include *Laminaria digitata*, *Ecklonia maxima*, *Macrocystis pyrifera*, *Lessonia nigrescens*, *Ascophyllum nodosum*, *Laminaria japonica*, *Durvillea antarctica*, *Durvillea potatorum* and especially, *Laminaria hyperborea*.

Alginic acid is a linear hetero-polysaccharide comprising units of  $\beta$ -D-mannuronic acid and  $\alpha$ -L-guluronic acid. Alginic acid may comprise homopolymeric sequences of mannuronic acid, homopolymeric sequences of guluronic acid, and mixed sequences of mannuronic acid and guluronic acid units.

Salts of alginic acid used may include alkali metal salts, for example sodium and potassium salts, and ammonium and alkanolamine salts. Alkali metal salts are of particular interest.

The term "algins" as used herein includes alginic acid and salts of alginic acid, irrespective of the relative proportion of mannuronic and guluronic units, and is intended to include glycolated or alkoxylated derivatives, especially those derivatised with propylene glycol. However, preferred compounds are not alkoxylated or glycolated.

Suitably the fibre ~~or saccharide~~ bulking agent is present in the ingestible composition in an amount of at least 10wt%, preferably at least 30wt%, and most preferably at least 40wt% of the total weight of the ingestible composition.

Suitably the fibre ~~or saccharide~~ bulking agent is present in the ingestible composition in an amount up to 90wt%, preferably up to 80wt%, and most preferably up to 75wt% of the total weight of the ingestible composition.

EJT 2/7/04

colloidal silica ~~silicon dioxide~~

Suitably the silica, is fumed or precipitated synthetic or natural silica. The silica may be amorphous or crystalline.

- 5 Suitably the mean particle size of the silica is at least 5nm, preferably at least 10nm.

Suitably the mean particle size of the silica is up to 5µm, preferably up to 0.75µm, more preferably up to 0.5µm,  
10 and most preferably up to 0.2µm.

Omit  
this  
section  
EJT 2/7/04

15 The silica material that is used may typically contain 0.1 to 2.5wt% alumina ( $Al_2O_3$ ), preferably 0.5 to 2wt% alumina, and most preferably about 1wt% alumina, based on the weight of the silica.

One suitable silica material is Syloid 244 which is amorphous silica, has a mean particle size of about 3µm and is provided by W R Grace & Co. Another suitable  
20 silica materials is Silox 15, also from W R Grace & Co., and which has a mean particle size of about 4µm.

Another suitable silica material is Huber Zep 49 which is amorphous silica from J M Huber Corporation and contains  
25 about 1 wt% alumina.

Another suitable silica is Aerosil 200 from Degussa Company. It contains less than 0.05 wt% alumina and has a mean particle size of 12 nm.

(silicon dioxide)

Preferably the silica is colloidal silica, and a preferred silica is a colloidal silica which is sold under the trade mark CAB-O-SIL, by Cabot Inc, USA.

- 5 Suitably the specific surface area of the silica is at least  $50\text{m}^2\text{g}^{-1}$ , preferably at least  $150\text{m}^2\text{g}^{-1}$ .

- Suitably the specific surface area of the silica is up to  $400\text{m}^2\text{g}^{-1}$ , preferably up to  $300\text{m}^2\text{g}^{-1}$  most preferably up to  $200\text{m}^2\text{g}^{-1}$ .
- 10

- Suitably the silica is present in the ingestible composition in an amount at least 0.01wt%, preferably at least 0.05wt%, more preferably at least 0.1wt% and most preferably at least 0.25wt%, of the total weight of the ingestible composition.
- 15

- 2. write in such way as to be amended*
- ~~The upper limit of silica in the ingestible composition may be up to 11 wt%. Suitably the silica may be present in the ingestible composition in an amount up to 5wt%, preferably up to 2wt%, more preferably up to 1wt%, and most preferably up to 0.6wt%, of the total weight of the ingestible composition.~~
- 20

- 25 Preferably the ingestible surfactant is a polyethylene-, polypropylene-, or polyoxyethylene-based surfactant. Suitable polyethylene or polyoxyethylene-based surfactants include polyethylene glycols and polyoxyethylene sorbitan fatty acid esters (polysorbates).

30

Suitable polyethylene glycols have a molecular weight of between 200 and 40,000, preferably between 200 and 1,000, and more preferably between 200 and 600. Suitable

5

Example 5

The wettability testing was repeated for a composition containing barley fibre as the bulking agent, Tween 80 and CAB-O-SIL. The samples were tested immediately on preparation. The results of the experiment are shown in Table 9.

15 Table 9 - Wetting times of Barley Fibre and Tween 80 / CAB-O-SIL Mixtures.

<u>Barley Fibre</u> (g)	<u>Tween 80</u> (mg)	<u>Cabosil</u> (mg)	<u>Wetting Time</u> (seconds)
3.5	0	0	>600
3.5	0	200	280
3.5	0	400	200
3.5	30	0	129
3.5	30	200	102
3.5	30	400	81
3.5	60	0	77
3.5	60	200	56
3.5	60	400	55
3.5	100	0	30
3.5	100	200	24
3.5	100	400	22

20 The results show that for a given amount of Tween, addition of CAB-O-SIL to the composition significantly improves wettability of barley fibre.

mit  
his  
action  
2/7/04

5 Example 6

The wettability testing was repeated for a composition containing green pea fibre as the bulking agent, Tween 80 and CAB-O-SIL. The samples were tested immediately on preparation. The results of the experiment are shown in Table 10.

Table 10 - Wetting times of Green Pea Fibre and Tween 80 / CABO-O-SIL Mixtures.

<u>Green Pea Fibre (g)</u>	<u>Tween 80 (mg)</u>	<u>Cabosil (mg)</u>	<u>Wetting Time (seconds)</u>
14.2	30	0	42
14.2	60	0	18
14	30	50	12
14	30	100	8
14	0	50	30
14	0	100	13

The results show that for a given amount of Tween, addition of CAB-O-SIL to the composition significantly improves the wettability of pea fibre.

20

25

omit this section  
JST  
2/7/04

5 Example 7

The wettability of sodium alginate as the bulking agent was tested. 0.5g of each sample was sprinkled over water and the time taken to wet was recorded.

10

<u>Sodium Alginate</u> (g)	<u>Tween</u> (g)	<u>Colloidal silica</u> (g)	<u>Wetting Time</u> (seconds)
1	-	-	25
0.97	-	0.03	20
0.952	0.04	0.008	15

(Table 11 shows the amounts of each component in a 1g sample. 0.5g of sample was used for each test).

- omit this section.  
JT  
4/7/04
- 15 The results show that the addition of Tween and colloidal silica significantly reduces wetting time. The reduction in wetting time is not only seen when compared with a sample of untreated sodium alginate but is also seen when compared with a sample containing sodium alginate and
- 20 colloidal silica. When Tween is added, significantly less colloidal silica is required to result in a significant reduction in the wetting time of the alginate.

5 Claims

colloidal

ispaghula,

1. An ingestible composition comprising ~~a fibre or~~  
~~saccharide bulking agent, an ingestible~~ silica, and an  
10 ingestible surfactant wherein said composition is in a  
form so that in use it is dispersed in a liquid prior to  
ingestion.

2. An ingestible composition according to claim 1 wherein  
said composition in particulate or granular form.

15

3. An ingestible composition as claimed in claim 1 or 2  
wherein the fibre bulking agent is ispaghula.

4. An ingestible composition as claimed in claim 1 or 2  
20 wherein the bulking agent is a polysaccharide-containing  
bulking agent comprising an algin.

5. An ingestible composition according to claim 1 or 2  
wherein the fibre bulking agent is cellulose or a  
25 derivative thereof.

6. An ingestible composition comprising a fibre bulking  
agent selected from ispaghula or a bran, an ingestible  
silica, and an ingestible surfactant.

30

7. An ingestible composition according to claim 6 wherein  
the fibre bulking agent is ispaghula.

3. ~~8.~~ An ingestible composition as claimed in any preceding  
35 claim wherein the particle size of the silica is between  
5nm and 5µm.

5 <sup>4</sup>  
~~9.~~ An ingestible composition as claimed in any preceding claim wherein the specific surface area of the silica is between 50 and 400gm<sup>-2</sup>.

10 <sup>5</sup>  
~~10.~~ An ingestible composition as claimed in any preceding claim wherein the silica is present in an amount of between 0.01wt% and 5wt% of the total weight of the ingestible composition.

15 <sup>6</sup>  
~~11.~~ An ingestible composition as claimed in any preceding claim, wherein the ingestible surfactant is a polyethylene-, polypropylene-, or polyoxyethylene-based surfactant.

20 <sup>7</sup>  
~~12.~~ An ingestible composition as claimed in claim 11 wherein the polyethylene-based surfactant is a polyethylene glycol.

25 <sup>8</sup>  
~~13.~~ An ingestible composition as claimed in claim 12 wherein the polyethylene glycol has a molecular weight of between 200 and 40,000, preferably between 200 and 1,000.

30 <sup>9</sup>  
~~14.~~ An ingestible composition as claimed in claim 11 wherein the polyoxyethylene-based surfactant is a polyoxyethylene sorbitan fatty acid ester.

<sup>10</sup>  
~~15.~~ An ingestible composition as claimed in claim 11, wherein the surfactant is a polyoxyethylene monostearate or a glycerol polyethylene glycol oxystearate.

35 <sup>11</sup>  
~~16.~~ An ingestible composition as claimed in any preceding claim wherein the ingestible surfactant is present in an

5 amount of between 0.01wt% and 5wt% of the total weight of  
the ingestible composition.

12  
17. An ingestible composition as claimed in claim 16  
wherein the ingestible surfactant is polyethylene glycol  
10 and is present in an amount of between 0.1wt% and 2wt% of  
the total weight of the ingestible composition.

13  
18. An ingestible composition as claimed in claim 16  
wherein the surfactant is a polyoxyethylene sorbitan fatty  
15 acid ester and is present in an amount of between 1wt% and  
2wt% of the total weight of the ingestible composition. 19.

14  
19. A method of making an ingestible composition  
comprising a fibre or <sup>ispaghula</sup> ~~saccharide~~ bulking agent, an  
20 <sup>colloidal</sup> ~~ingestible~~ silica, and an ingestible surfactant, the  
method comprising the step of blending the <sup>ispaghula</sup> ~~fibre~~ <sup>or</sup> ~~saccharide~~  
<sup>the colloidal</sup> ~~ingestible~~ silica and  
the ingestible surfactant; preferably without the  
employment of isopropyl alcohol or more preferably of any  
25 solvent; and preferably without the employment of  
polyvinyl pyrrolidone or more preferably of any  
granulating agent.

15  
20. An ingestible composition or its manufacture  
30 substantially as described herein.